Volume 12, Number 4, April 2006

Economic Impact of Lyme Disease

Xinzhi Zhang,* Martin I. Meltzer,* César A. Peña,† Annette B. Hopkins,† Lane Wroth,‡ and Alan D. Fix†
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †University of Maryland, Baltimore, Maryland, USA; and ‡Care First-Easton Branch (previously Delmarva Health Plan), Easton, Maryland, USA

Figure 3. Expected mean (median) cost per Lyme disease (LD) patient in Maryland Eastern Shore by using LD outcome tree. Direct medical costs collected from medical record abstraction (1997–2000). Indirect medical costs, nonmedical costs, and productivity losses were acquired from patient questionnaire (1998–1999). The mean (median) of all costs was aggregated across all diagnostic groups of patients. Percentages refer to probabilities of outcome of a possible LD case (clinically defined early-stage LD, clinically defined late-stage LD, suspected LD, tick bite, and other related complaints). Total percentages do not add to 100% because of rounding. All costs were converted to 2000 equivalent.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed March 21, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention